{"id":"NCT00706589","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder","officialTitle":"A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2008-06-27","resultsPosted":"2013-07-26","lastUpdate":"2013-07-26"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Motor or Vocal Tic Disorder","Tourette's Disorder"],"interventions":[{"type":"DRUG","name":"aripiprazole","otherNames":["Abilify"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6\\~18 years with chronic tic disorders or Tourette's disorder","primaryOutcome":{"measure":"Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)","timeFrame":"10 week","effectByArm":[{"arm":"Aripiprazole","deltaMin":-9.62,"sd":null},{"arm":"Placebo","deltaMin":-14.97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["South Korea"]},"refs":{"pmids":["24021518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Nausea","Sedation","Akathisia","Headache","Dizziness"]}}